Handelsbanken Fonder AB Has $31.51 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Handelsbanken Fonder AB boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 114.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 116,683 shares of the biopharmaceutical company's stock after purchasing an additional 62,337 shares during the period. Handelsbanken Fonder AB owned approximately 0.09% of Alnylam Pharmaceuticals worth $31,507,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of ALNY. Larson Financial Group LLC grew its position in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 73 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $28,000. Whipplewood Advisors LLC grew its position in Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 71 shares in the last quarter. OFI Invest Asset Management acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $35,000. Finally, Colonial Trust Co SC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $35,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded up $6.97 during trading hours on Thursday, hitting $305.55. The company had a trading volume of 232,488 shares, compared to its average volume of 927,522. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm has a market capitalization of $39.84 billion, a price-to-earnings ratio of -140.81 and a beta of 0.22. Alnylam Pharmaceuticals, Inc. has a 12 month low of $152.30 and a 12 month high of $310.22. The firm's fifty day moving average is $266.98 and its 200 day moving average is $258.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. The firm's revenue was up 20.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.16) earnings per share. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ALNY. Wall Street Zen raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Wells Fargo & Company raised their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research note on Friday, March 21st. Royal Bank of Canada lifted their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a report on Friday, March 21st. Bank of America upped their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a report on Friday, March 21st. Finally, Citigroup lifted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $319.58.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the company's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the sale, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at $14,899,281.72. This represents a 39.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.